Allergy Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Allergy Type, By Test, By End User, By Region & Competition, 2021-2031F

Description

The Global Allergy Diagnostics Market is projected to expand from USD 6.58 Billion in 2025 to USD 12.98 Billion by 2031, achieving a CAGR of 11.99%. This sector involves the medical instruments, consumables, and assays used to identify allergen-specific antibodies or cellular responses, enabling the clinical diagnosis of hypersensitivities to environmental and food-based triggers. Market growth is primarily fueled by the rising global incidence of atopic diseases and the clinical necessity for early detection to manage chronic conditions effectively. As reported by the Asthma and Allergy Foundation of America in 2024, approximately 100 million individuals in the United States live with various allergic conditions, underscoring the critical need for reliable diagnostic frameworks to address this expanding health burden.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 6.58 Billion
Market Size 2031	USD 12.98 Billion
CAGR 2026-2031	11.99%
Fastest Growing Segment	Assay Kits
Largest Market	Asia Pacific

However, the market encounters significant hurdles due to the high acquisition and operational costs associated with automated diagnostic platforms. These financial constraints frequently limit the adoption of comprehensive testing panels in smaller laboratories and resource-limited healthcare settings. Consequently, high costs impede market penetration in developing economic regions where healthcare budgets are tight, effectively restricting the widespread availability of these essential diagnostic tools.

Market Driver

The rising global prevalence of allergic diseases and comorbidities, exacerbated by rapid urbanization and environmental pollution, serves as a primary catalyst for the growth of the allergy diagnostics market. As climate change degrades air quality and prolongs pollen seasons, the frequency of respiratory sensitizations has increased, creating a demand for more frequent and precise screening protocols. According to the March 2024 '2024 Allergy Capitals' report by the Asthma and Allergy Foundation of America, approximately 25.7% of adults in the United States have a diagnosed seasonal allergy. This widespread burden compels healthcare providers to utilize comprehensive diagnostic panels to distinguish allergic rhinitis from other respiratory conditions, thereby boosting the deployment of immunoassay analyzers and consumable kits in clinical settings.

Simultaneously, the market is significantly propelled by the surging incidence of severe food allergies and dietary sensitivities, which necessitate accurate risk assessment tools. The complexity of food-based hypersensitivities has shifted clinical focus toward component-resolved diagnostics to pinpoint specific proteins that trigger anaphylaxis. In the 'The clinical burden of food allergies' article published by the World Allergy Organization in March 2024, 46% of patients in the FARE Patient Registry reported experiencing food-induced anaphylaxis, highlighting the need for advanced stratification. Furthermore, the Food Standards Agency's August 2024 report noted that hospital admissions for food-induced anaphylaxis in England rose to 4.02 per 100,000 people, reinforcing the urgent clinical imperative for robust diagnostic interventions.

Market Challenge

The substantial acquisition and operational expenses tied to automated diagnostic platforms pose a major restraint on the expansion of the allergy diagnostics market. Small and medium-sized laboratories often lack the capital budget necessary to purchase these instruments or support the recurring costs of consumables and maintenance. This financial barrier effectively restricts the use of comprehensive testing panels to well-funded medical centers, leaving smaller facilities and resource-constrained regions underserved. Consequently, the market struggles to penetrate developing economic regions where healthcare spending is strictly monitored and prioritized.

According to the European Academy of Allergy and Clinical Immunology, approximately 150 million citizens across Europe were estimated to suffer from chronic allergic diseases in 2024. Despite this high prevalence and the associated need for diagnosis, the inability of smaller healthcare providers to afford automated systems creates a disparity between clinical demand and testing availability. When diagnostic infrastructure is financially inaccessible to a large segment of the healthcare landscape, patient access is reduced, which directly limits the volume of assays performed and impedes overall market growth.

Market Trends

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into diagnostic workflows is fundamentally transforming allergy testing by automating the interpretation of complex immunological data. These advanced algorithms analyze patient history and sensitization patterns to predict allergen reactivity with greater precision than traditional manual assessments, significantly lowering administrative burdens on clinicians. As detailed in the 'AI-Enhanced Allergy Diagnostics' article within the European Journal of Public Health in October 2024, clinical trials involving around 300 patients showed that AI-supported methods saved medical staff an average of 40 minutes per patient while maintaining high sensitivity. This technological shift addresses specialist shortages by streamlining the stratification of high-risk patients and optimizing clinical decision-making.

Concurrently, the market is witnessing a decisive shift toward Multiplex Immunoassay and Microarray Platforms, which allow for the simultaneous quantification of specific IgE antibodies against a vast array of allergens from a single serum sample. This evolution supports the broader adoption of Component-Resolved Diagnostics (CRD), enabling practitioners to differentiate between genuine sensitization and cross-reactivity more effectively than single-plex assays. A significant advancement in this area was highlighted by AliveDx in a July 2024 press release, announcing regulatory approval for its proprietary microarray immunoassay designed to detect over 30 distinct allergens, including both food and inhalant proteins. Such platforms are increasingly critical for developing personalized management plans for polysensitized individuals without requiring large blood volumes.

Key Market Players

Thermo Fisher Scientific Inc.
Siemens Healthineers AG
Abbott Laboratories
Danaher Corporation
Hologic, Inc.
BioMerieux SA
F. Hoffmann-La Roche AG
Laboratory Corporation of America Holdings
Allergy Therapeutics plc
Indoor Biotechnologies, Inc.

Report Scope

In this report, the Global Allergy Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Diagnostics Market, By Product

Assay Kits
Instruments
Consumables
Services

Allergy Diagnostics Market, By Allergy Type

Food
Seasonal
Drug
Inhalant
Anaphylaxis/Contact Allergies
Others

Allergy Diagnostics Market, By Test

In Vivo
In Vitro

Allergy Diagnostics Market, By End User

Hospital
Diagnostic Laboratory
Academic and Research Institutes
Others

Allergy Diagnostics Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Diagnostics Market.

Available Customizations:

Global Allergy Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Diagnostics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Assay Kits, Instruments, Consumables, Services)
- 5.2.2. By Allergy Type (Food, Seasonal, Drug, Inhalant, Anaphylaxis/Contact Allergies, Others)
- 5.2.3. By Test (In Vivo, In Vitro)
- 5.2.4. By End User (Hospital, Diagnostic Laboratory, Academic and Research Institutes, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America Allergy Diagnostics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Allergy Type
- 6.2.3. By Test
- 6.2.4. By End User
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Allergy Diagnostics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Allergy Type
    - 6.3.1.2.3. By Test
    - 6.3.1.2.4. By End User
- 6.3.2. Canada Allergy Diagnostics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Allergy Type
    - 6.3.2.2.3. By Test
    - 6.3.2.2.4. By End User
- 6.3.3. Mexico Allergy Diagnostics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Allergy Type
    - 6.3.3.2.3. By Test
    - 6.3.3.2.4. By End User

7. Europe Allergy Diagnostics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Allergy Type
- 7.2.3. By Test
- 7.2.4. By End User
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Allergy Diagnostics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Allergy Type
    - 7.3.1.2.3. By Test
    - 7.3.1.2.4. By End User
- 7.3.2. France Allergy Diagnostics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Allergy Type
    - 7.3.2.2.3. By Test
    - 7.3.2.2.4. By End User
- 7.3.3. United Kingdom Allergy Diagnostics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Allergy Type
    - 7.3.3.2.3. By Test
    - 7.3.3.2.4. By End User
- 7.3.4. Italy Allergy Diagnostics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Allergy Type
    - 7.3.4.2.3. By Test
    - 7.3.4.2.4. By End User
- 7.3.5. Spain Allergy Diagnostics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Allergy Type
    - 7.3.5.2.3. By Test
    - 7.3.5.2.4. By End User

8. Asia Pacific Allergy Diagnostics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Allergy Type
- 8.2.3. By Test
- 8.2.4. By End User
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Allergy Diagnostics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Allergy Type
    - 8.3.1.2.3. By Test
    - 8.3.1.2.4. By End User
- 8.3.2. India Allergy Diagnostics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Allergy Type
    - 8.3.2.2.3. By Test
    - 8.3.2.2.4. By End User
- 8.3.3. Japan Allergy Diagnostics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Allergy Type
    - 8.3.3.2.3. By Test
    - 8.3.3.2.4. By End User
- 8.3.4. South Korea Allergy Diagnostics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Allergy Type
    - 8.3.4.2.3. By Test
    - 8.3.4.2.4. By End User
- 8.3.5. Australia Allergy Diagnostics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Allergy Type
    - 8.3.5.2.3. By Test
    - 8.3.5.2.4. By End User

9. Middle East & Africa Allergy Diagnostics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Allergy Type
- 9.2.3. By Test
- 9.2.4. By End User
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Allergy Diagnostics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Allergy Type
    - 9.3.1.2.3. By Test
    - 9.3.1.2.4. By End User
- 9.3.2. UAE Allergy Diagnostics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Allergy Type
    - 9.3.2.2.3. By Test
    - 9.3.2.2.4. By End User
- 9.3.3. South Africa Allergy Diagnostics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Allergy Type
    - 9.3.3.2.3. By Test
    - 9.3.3.2.4. By End User

10. South America Allergy Diagnostics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Allergy Type
- 10.2.3. By Test
- 10.2.4. By End User
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Allergy Diagnostics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Allergy Type
    - 10.3.1.2.3. By Test
    - 10.3.1.2.4. By End User
- 10.3.2. Colombia Allergy Diagnostics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Allergy Type
    - 10.3.2.2.3. By Test
    - 10.3.2.2.4. By End User
- 10.3.3. Argentina Allergy Diagnostics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Allergy Type
    - 10.3.3.2.3. By Test
    - 10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Allergy Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Thermo Fisher Scientific Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Siemens Healthineers AG
15.3. Abbott Laboratories
15.4. Danaher Corporation
15.5. Hologic, Inc.
15.6. BioMerieux SA
15.7. F. Hoffmann-La Roche AG
15.8. Laboratory Corporation of America Holdings
15.9. Allergy Therapeutics plc
15.10. Indoor Biotechnologies, Inc.